Kevin Kalinsky

8.3k total citations · 2 hit papers
150 papers, 3.1k citations indexed

About

Kevin Kalinsky is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Kevin Kalinsky has authored 150 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 107 papers in Oncology, 77 papers in Pulmonary and Respiratory Medicine and 43 papers in Cancer Research. Recurrent topics in Kevin Kalinsky's work include Advanced Breast Cancer Therapies (63 papers), HER2/EGFR in Cancer Research (53 papers) and Cancer Treatment and Pharmacology (44 papers). Kevin Kalinsky is often cited by papers focused on Advanced Breast Cancer Therapies (63 papers), HER2/EGFR in Cancer Research (53 papers) and Cancer Treatment and Pharmacology (44 papers). Kevin Kalinsky collaborates with scholars based in United States, Spain and France. Kevin Kalinsky's co-authors include Aditya Bardia, Sara M. Tolaney, Hope S. Rugo, David M. Goldenberg, Joyce O’Shaughnessy, William A. Wegener, Jennifer R. Diamond, Linda T. Vahdat, Robert M. Sharkey and Vandana G. Abramson and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Kevin Kalinsky

135 papers receiving 3.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer

2019 599 citations Aditya Bardia, Sara M. Tolaney et al. profile →
Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression

2024 71 citations Aditya Bardia, Hope S. Rugo et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kevin Kalinsky United States	30	2.1k	994	853	728	559	150	3.1k
Philippe Aftimos Belgium	25	1.9k 0.9×	809 0.8×	934 1.1×	785 1.1×	690 1.2×	144	3.1k
Rashmi K. Murthy United States	24	2.3k 1.1×	974 1.0×	644 0.8×	599 0.8×	839 1.5×	85	2.9k
Zefei Jiang China	30	2.5k 1.2×	1.2k 1.2×	1.1k 1.3×	915 1.3×	744 1.3×	198	3.8k
Valentina Boni Spain	29	2.3k 1.1×	772 0.8×	1.0k 1.2×	771 1.1×	771 1.4×	189	3.4k
Giancarlo Bisagni Italy	25	1.9k 0.9×	832 0.8×	570 0.7×	747 1.0×	918 1.6×	127	2.9k
Maya Gutierrez France	19	1.9k 0.9×	925 0.9×	1.0k 1.2×	911 1.3×	371 0.7×	31	3.0k
Dimitrios Zardavas Belgium	21	2.1k 1.0×	854 0.9×	945 1.1×	1.3k 1.8×	589 1.1×	69	3.3k
Giorgio Valabrega Italy	28	1.8k 0.9×	490 0.5×	946 1.1×	497 0.7×	577 1.0×	115	2.8k
Jennifer R. Diamond United States	26	2.0k 1.0×	756 0.8×	998 1.2×	469 0.6×	400 0.7×	136	3.0k
José Manuel Pérez-García Spain	26	2.0k 0.9×	962 1.0×	1.5k 1.7×	891 1.2×	239 0.4×	110	3.5k

Countries citing papers authored by Kevin Kalinsky

Since Specialization

Citations

This map shows the geographic impact of Kevin Kalinsky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kevin Kalinsky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kevin Kalinsky more than expected).

Fields of papers citing papers by Kevin Kalinsky

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kevin Kalinsky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kevin Kalinsky. The network helps show where Kevin Kalinsky may publish in the future.

Co-authorship network of co-authors of Kevin Kalinsky

This figure shows the co-authorship network connecting the top 25 collaborators of Kevin Kalinsky. A scholar is included among the top collaborators of Kevin Kalinsky based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kevin Kalinsky. Kevin Kalinsky is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Thomas, Alexandra, Anthony Rhoads, Erica L. Mayer, et al.. (2025). Evolving incidence patterns for locally advanced operable breast cancer by receptor status: SEER 2010–2021. npj Breast Cancer. 11(1). 127–127.

Bardia, Aditya, Hope S. Rugo, Mina S. Sedrak, et al.. (2025). Q-TWiST Analysis to Assess Benefit-Risk of Sacituzumab Govitecan in Previously Treated Patients With Metastatic Triple-Negative Breast Cancer. JCO Oncology Practice. OP2400806–OP2400806. 1 indexed citations

Moore, George E., et al.. (2024). Administration of trastuzumab deruxtecan in metastatic breast cancer patients with severe hepatic impairment. SHILAP Revista de lepidopterología. 16. 100337–100337. 1 indexed citations

Bardia, Aditya, Lajos Pusztai, Kathy S. Albain, et al.. (2024). TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy. Therapeutic Advances in Medical Oncology. 16. 12693072–12693072. 16 indexed citations

Pernas, Sònia, Seock‐Ah Im, Masaya Hattori, et al.. (2024). Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Patient-reported outcomes (PROs) from the TROPION-Breast01 study.. Journal of Clinical Oncology. 42(16_suppl). 1006–1006. 1 indexed citations

Lloyd, Maxwell R., Caroline Weipert, Jayati Saha, et al.. (2024). Real-world (RW) elacestrant use patterns and therapeutic outcomes in patients (pts) with hormone receptor-positive (HR+)/HER2-negative advanced breast cancer (aBC).. Journal of Clinical Oncology. 42(16_suppl). 1071–1071. 1 indexed citations

Kalinsky, Kevin, William E. Barlow, Harsh B. Pathak, et al.. (2024). Correlation of serum anti-Müllerian hormone (AMH) levels on identification of premenopausal patients (pts) with hormone receptor positive (HR+), HER2-negative, node-positive breast cancer most likely to benefit from adjuvant chemotherapy in SWOG S1007 (RxPONDER).. Journal of Clinical Oncology. 42(16_suppl). 505–505. 5 indexed citations

Chow, Angela, Seo-Young Han, Courtney Coker, et al.. (2024). FLT1 activation in cancer cells promotes PARP-inhibitor resistance in breast cancer. EMBO Molecular Medicine. 16(8). 1957–1980. 2 indexed citations

Jagsi, Reshma, William E. Barlow, Wendy A. Woodward, et al.. (2023). Radiotherapy Use and Incidence of Locoregional Recurrence in Patients With Favorable-Risk, Node-Positive Breast Cancer Enrolled in the SWOG S1007 Trial. JAMA Oncology. 9(8). 1083–1083. 6 indexed citations

10.

Hecht, J. Randolph, Steven S. Raman, Arlene Chan, et al.. (2023). Phase Ib study of talimogene laherparepvec in combination with atezolizumab in patients with triple negative breast cancer and colorectal cancer with liver metastases. ESMO Open. 8(2). 100884–100884. 22 indexed citations

11.

Fu, Ziyi, Siqi Chen, Yueming Zhu, et al.. (2023). Proteolytic regulation of CD73 by TRIM21 orchestrates tumor immunogenicity. Science Advances. 9(1). eadd6626–eadd6626. 18 indexed citations

12.

Qing, Tao, Thomas Karn, Mariya Rozenblit, et al.. (2022). Molecular differences between younger versus older ER-positive and HER2-negative breast cancers. npj Breast Cancer. 8(1). 119–119. 13 indexed citations

13.

Tolaney, Sara M., Kevin Kalinsky, Virginia Kaklamani, et al.. (2021). Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study. Clinical Cancer Research. 27(11). 3061–3068. 90 indexed citations

14.

Griffiths, Jason I., Jinfeng Chen, Patrick A. Cosgrove, et al.. (2021). Serial single-cell genomics reveals convergent subclonal evolution of resistance as patients with early-stage breast cancer progress on endocrine plus CDK4/6 therapy. Nature Cancer. 2(6). 658–671. 41 indexed citations

15.

Wright, Jason D., Grace Clarke Hillyer, Meghna S. Trivedi, et al.. (2021). Care Delivery Impact of the COVID-19 Pandemic on Breast Cancer Care. JCO Oncology Practice. 17(8). e1215–e1224. 39 indexed citations

16.

Kittaneh, Muaiad, Sunil Badve, Humberto Caldera, et al.. (2020). Case-Based Review and Clinical Guidance on the Use of Genomic Assays for Early-Stage Breast Cancer: Breast Cancer Therapy Expert Group (BCTEG). Clinical Breast Cancer. 20(3). 183–193. 12 indexed citations

17.

Hershman, Dawn L., Melissa Accordino, Sherry Shen, et al.. (2020). Association between nonadherence to cardiovascular risk factor medications after breast cancer diagnosis and incidence of cardiac events. Cancer. 126(7). 1541–1549. 13 indexed citations

18.

Kim, Hyun Koo, et al.. (2019). Diffuse optical tomography of the breast: a potential modifiable biomarker of breast cancer risk with neoadjuvant chemotherapy. Biomedical Optics Express. 10(8). 4305–4305. 11 indexed citations

19.

Lim, Emerson A., Jacqueline Gunther, Hyun Koo Kim, et al.. (2017). Diffuse optical tomography changes correlate with residual cancer burden after neoadjuvant chemotherapy in breast cancer patients. Breast Cancer Research and Treatment. 162(3). 533–540. 13 indexed citations

20.

Kalinsky, Kevin, Lindsay M. Jacks, Adriana Heguy, et al.. (2009). PIK3CA Mutation Associates with Improved Outcome in Breast Cancer. Clinical Cancer Research. 15(16). 5049–5059. 299 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact